Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
2.510
-0.290 (-10.36%)
At close: Oct 1, 2026, 4:00 PM EDT
2.450
-0.060 (-2.39%)
After-hours: Oct 1, 2026, 7:59 PM EDT
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
2.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| SciSparc | 856.00K |
| BioRestorative Therapies | 357.87K |
| Silo Pharma | 54.08K |
| Alaunos Therapeutics | 3.00K |
VBIO News
- 1 day ago - Valion Bio, Shear Kershman formulate oral mucosal entolimod - TheFly
- 1 day ago - Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity - Accesswire
- 8 days ago - Valion Bio appoints Dean Zikria as interim CEO, Thomas Jensen as chair - TheFly
- 8 days ago - Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions - Accesswire
- 9 days ago - Valion Bio regains compliance with Nasdaq minimum bid price listing rule - TheFly
- 9 days ago - Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule - Accesswire
- 4 weeks ago - Valion Bio appoints CFO Lisa Wolf as president, COO - TheFly
- 4 weeks ago - Valion Bio Announces Changes to Management and Board of Directors - Accesswire